News Channels

05 Sep 2023 BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
05 Sep 2023 Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
05 Sep 2023 Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
05 Sep 2023 uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
05 Sep 2023 Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
05 Sep 2023 X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
05 Sep 2023 XtalPi and Parthenon Enter Into AI-Powered Antibody Discovery Partnership
05 Sep 2023 Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
05 Sep 2023 Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy
05 Sep 2023 Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
05 Sep 2023 Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
05 Sep 2023 ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
05 Sep 2023 Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia
05 Sep 2023 Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate
05 Sep 2023 Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
05 Sep 2023 ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001
05 Sep 2023 invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
04 Sep 2023 iNtRON Signs Bacteriophage Development Project with U.S. Army DEVCOM
04 Sep 2023 Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
04 Sep 2023 Stallergenes Greer Announces Global Agreement With Nestlé Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia®

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up